Compare Diageo plc (DEO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Twist Bioscience Corp — how do they compare? Diageo plc trades at $81.1 (market cap $45.41B), while Twist Bioscience Corp trades at $92.62 (market cap $5.77B). The key difference: Diageo plc is far larger — about 7.9× Twist Bioscience Corp's market cap, and Diageo plc pays a 4.02% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| DEO | TWST | |
|---|---|---|
Market Cap | $45.41B | $5.77B |
Sector | Technology | Health |
52-Week High | $115.33 | $102.88 |
52-Week Low | $72.47 | $24.16 |
Enterprise Value | $66.23B | $5.69B |
Dividend Yield | 4.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $82.50, up 0.57% today, with a bullish technical trend and strong profitability metrics including a 12.19% net margin and 22.29% ROE. Recent earnings show mixed results with a Q4 2025 beat but a Q2 2025 miss, while analyst sentiment is positive with 49% buy ratings. The stock faces headwinds from weak U.S. spirits demand and promotional pressures, as noted in recent Deutsche Bank and UBS reports from July 2026.
The outlook hinges on management's strategy reset in August 2026 to address U.S. volume declines and margin pressures. Investment appeal lies in its discounted valuation relative to historical multiples and dividend yield, but risks include sustained consumer moderation trends and execution challenges in key markets.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
